Elsevier

Comprehensive Psychiatry

Volume 41, Issue 1, January–February 2000, Pages 63-69
Comprehensive Psychiatry

Assessment of social functioning in depression

https://doi.org/10.1016/S0010-440X(00)90133-0Get rights and content

Abstract

Impairment of social functioning is a significant aspect of depression distinct from the symptoms of depression. Social functioning defines an individual's interactions with their environment and the ability to fulfill their role within such environments as work, social activities, and relationships with partners and family. The analysis of social functioning has arisen from a growing interest in measuring the consequences of depression and antidepressant therapy. Impairment often persists long after the resolution of symptoms by pharmacotherapy, and is not extensively assessed by the traditional scales to measure the intensity of depressive symptoms. Assessment is influenced by the method used, and there is an increased awareness that the patient's perspective should be foremost. Several scales for the evaluation of social functioning have already been developed, ranging from those requiring a structured interview with a trained assessor to self-assessment scales. In constructing such tools, a balance must be found between the amount of detail required to produce a clear account of the patient's social functioning and the ease of use in large multicenter studies. The newest scale is the Social Adaptation Self-evaluation Scale (SASS), specifically for self-assessment of social functioning by patients with depression. It contains 21 items covering the different aspects of social interactions, global social attitude, and self-perception. The SASS has been validated and found to be simple to use and sensitive to changes in the different areas of social functioning. Recently, the SASS was used to demonstrate the greater efficacy of reboxetine, a new selective noradrenaline reuptake inhibitor (selective NRI), compared with the selective serotonin reuptake inhibitor (SSRI) fluoxetine, in improving social functioning in patients with depression. Specifically, the SASS was able to show that reboxetine improved patient motivation and self-perception. The SASS is another tool for the evaluation of the extent and quality of the response to treatment and may also help to elucidate the roles of noradrenaline and serotonin in depressive illness.

References (38)

  • G. Stefos et al.

    Psychosocial predictors of major affective recurrences in bipolar disorder: a 4-year longitudinal study of patients on prophylactic treatment

    Acta Psychiatr Scand

    (1996)
  • R.D. Hays et al.

    Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses

    Arch Gen Psychiatry

    (1995)
  • A. Dubini et al.

    Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning

    J Psychopharmacol

    (1997)
  • P.L. Delgado et al.

    Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression

    Psychopharmacol Bull

    (1991)
  • P.L. Delgado et al.

    Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants

    Psychopharmacol Bull

    (1993)
  • H.L. Miller et al.

    Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression

    Arch Gen Psychiatry

    (1996)
  • D.S. Charney

    Monoamine dysfunction and the pathophysiology and treatment of depression

    J Clin Psychiatry

    (1998)
  • M. Hamilton

    A rating scale for depression

    J Neurol Neurosurg Psychiatry

    (1960)
  • A.T. Beck

    Cognitive Therapy and Emotional Disorders

  • Cited by (0)

    View full text